Combination Study of BMS-754807 and Erbitux® in Subjects With Advanced or Metastatic Solid Tumors

Stopped early · Phase 1/Phase 2

Conditions studied: Colorectal Cancer, Head and Neck Cancer, Neoplasm Metastasis

In brief

The study is expected to identify a safe dose of BMS-754807 to be given in combination with a standard dose of cetuximab and the recommended dose or dose range for Phase II studies. The study is also intended to collect first data on the effects of the combination of BMS-754807 with cetuximab on tumors of patients with colorectal cancer or squamous cell cancer of the head and neck for whom cetuximab-containing therapies have not been effective

Key facts

Study ID

NCT00908024

Run by

Bristol-Myers Squibb

People needed

54

Starts

2009-10-01

Expected to finish

2012-12-01

Last updated by the study team

2013-06-18

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• ECOG status 0 - 1
• Dose escalation: Subjects with locally advanced or metastatic solid tumors who are eligible to receive cetuximab treatment and have archived tumor biopsy material available. Colorectal cancer subjects must be confirmed KRAS wild type
• Dose expansion: CRC (KRAS-WT) and head \& neck cancer subjects only
• must be able to provide 2 fresh tumor biopsy samples
• must have failed one prior cetuximab-containing treatment

You may not qualify if…

• Symptomatic brain metastasis
• Prior treatments with anti-EGFR (except cetuximab) or anti-IGF-1R agents, experimental or licensed
• Any condition requiring chronic use of steroids
• Any disorder with dysregulation of glucose homeostasis (history of Type 1 or 2 Diabetes Mellitus or prediabetic symptoms)
• History of glucose intolerance
• History of cetuximab infusion reactions
• Women of child-bearing potential unwilling or unable to use acceptable contraception methods

Where it is running

• Nebraska Methodist Hospital — Omaha, Nebraska, United States
• Duke University Medical Center — Durham, North Carolina, United States
• University Of Wisconsin — Madison, Wisconsin, United States
• Local Institution — Vancouver, British Columbia, Canada
• Local Institution — Toronto, Ontario, Canada

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.